

Supporting Information

Ortho-C–O Arylation of Aromatic Amides with Grignard Reagents

Ya Wu, Bohao Wang, Yiran Shi, Pei Liu, Jie Kong

Table of Contents

1. Materials and Methods	1
2. Procedures for the Preparation of Substituted Benzamides ¹	2
3. Optimizing Reaction Parameters	11
4. General Procedure for the <i>Ortho</i> -C–O Arylation of Aromatic Amides with Grignard Reagents through Meyers Reaction	13
5. Supplementary References	23
6. ¹ H, ¹³ C and ¹⁹ F NMR Spectra	24

1. Materials and Methods


General. All reactions dealing with air- or moisture-sensitive compounds were carried out in a flame-dried, sealed Schlenk reaction tube under an atmosphere of nitrogen. Analytical thin-layer chromatography was performed on glass plates coated with 0.25 mm 230–400 mesh silica gel containing a fluorescent indicator (Merck). Flash silica gel column chromatography was performed on silica gel 60N (spherical and neutral, 140–325 mesh) as described by Still. NMR spectra were measured on a Bruker AV-400 spectrometer and reported in parts per million. ^1H NMR spectra were recorded at 400 MHz or 500 MHz in CDCl_3 were referenced internally to tetramethylsilane as a standard, and ^{13}C NMR spectra were recorded at 100 MHz or 125 MHz and referenced to the solvent resonance. High resolution mass spectra (HRMS) were recorded on the Exactive Mass Spectrometer (Thermo Scientific, USA) equipped with ESI ionization source.

Materials. Unless otherwise noted, materials were purchased from Tokyo Chemical Industry Co., Aldrich Inc., Alfa Aesar, Adamas, and other commercial suppliers and used as received. Solvents were dried over sodium (for THF and ether) by refluxing for overnight and freshly distilled prior to use. Grignard reagents were purchased from commercial suppliers.

2.Procedures for the Preparation of Substituted Benzamides¹

General procedure A:

In a dried flask, substituted amine (1.0 equiv), 2-oxo-substituted benzoic acid (1.2 equiv), 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC, 2.0 equiv) and 4-Dimethylaminopyridine (DMAP, 2.0 equiv) were dissolved in DCM. The resulting solution was stirring at room temperature for 12 h. After the reaction completed, added the DCM and the resulting mixture was washed with H₂O. The combined organic phase was dried over anhydrous Na₂SO₄ and concentrated under vacuum. The crude product was then purified by flash chromatography on silica gel to give the substituted benzamides.





General procedure B:

Step 1: A mixture of phenol (1.2 equiv), 2-fluorobenzonitrile (1.0 equiv) and K₂CO₃ (3.0 equiv) in DMF (0.2 M) was stirred at 170 °C under Ar atmosphere for 12 h. Then the reaction mixture was cooled to room temperature and the insoluble solid was removed by filtration, washed with EtOAc. Then water was added to the liquid mixture. The organic layer was separated and the aqueous layer was extracted by EtOAc for three times. The combined organic extracts were washed with 5% NaOH, H₂O, brine and dried over anhydrous Na₂SO₄. Evaporation of the solvent gave the crude product **S1** which was used without any further purification.


Step 2: A mixture of NaOH (7.5 equiv), H₂O/EtOH (1:1, 0.2 M) and the crude product **S1** (1.0 equiv) was stirred under reflux for 12 h. After cooling to room temperature, water was added and the mixture was extracted with EtOAc. Then the aqueous phase was acidified with HCl (1.0 M) and extracted with EtOAc for three times. The combined organic extracts were washed with brine and dried over anhydrous Na₂SO₄. The residue was purified by silica gel chromatography to afford compound **S2**.

Step 3: substituted benzamides was prepared from the corresponding substituted amine and 2-oxo-substituted benzoic acid according to the **general procedure A**.




***N*-methyl-2-phenoxybenzamide (1a)**

R_f (5:1 hexanes-EtOAc) 0.41. ^1H NMR (500 MHz, CDCl_3) δ 8.24 (dd, $J = 7.9, 1.7$ Hz, 1H), 7.67 (s, 1H), 7.38 (t, $J = 8.0$ Hz, 2H), 7.33 (td, $J = 8.4, 1.8$ Hz, 1H), 7.18 (dt, $J = 14.9, 7.3$ Hz, 2H), 7.05 (d, $J = 7.8$ Hz, 2H), 6.78 (d, $J = 8.2$ Hz, 1H), 2.97 (d, $J = 4.9$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 165.4, 155.6, 155.3, 132.4, 132.1, 130.1, 124.7, 123.7, 123.4, 119.8, 117.9, 26.6. HRMS (ESI $^+$): calcd for $\text{C}_{14}\text{H}_{14}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 228.10245, found 228.10263. Spectroscopic data are in accordance with those described in the literature²




***N*-isopropyl-2-phenoxybenzamide (1b)**

R_f (6:1 hexanes-EtOAc) 0.37. ^1H NMR (500 MHz, CDCl_3) δ 8.21 (dd, $J = 7.9, 1.8$ Hz, 1H), 7.41 (s, 1H), 7.38 – 7.34 (m, 3H), 7.23 – 7.19 (m, 1H), 7.16 (t, $J = 7.4$ Hz, 1H), 7.00 (d, $J = 7.8$ Hz, 2H), 6.86 (d, $J = 8.2$ Hz, 1H), 4.28 – 4.18 (m, 1H), 1.14 (d, $J = 6.6$ Hz, 6H). ^{13}C NMR (125 MHz, CDCl_3) δ 163.7, 155.9, 154.6, 132.4, 132.1, 130.0, 125.0, 124.2, 124.0, 119.1, 118.6, 41.5, 22.6. HRMS (ESI $^+$): calcd for $\text{C}_{16}\text{H}_{18}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 256.13375, found 256.13329. Spectroscopic data are in accordance with those described in the literature.²




***N*-(tert-butyl)-2-phenoxybenzamide (1c)**

R_f (8:1 hexanes-EtOAc) 0.35. ^1H NMR (400 MHz, CDCl_3) δ 8.20 (dd, $J = 7.9, 1.8$ Hz, 1H), 7.50 (s, 1H), 7.41 – 7.33 (m, 3H), 7.23 (t, $J = 7.5$ Hz, 1H), 7.15 (t, $J = 7.4$ Hz, 1H), 6.99 (d, $J = 8.0$ Hz, 2H), 6.90 (d, $J = 8.1$ Hz, 1H), 1.36 (s, 9H). ^{13}C NMR (125 MHz, CDCl_3) δ 163.7, 156.2, 154.1, 132.3, 131.9, 130.1, 126.2, 124.3, 124.0, 119.5, 118.2, 51.2, 28.7. HRMS (ESI⁺): calcd for $\text{C}_{17}\text{H}_{20}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 270.14940, found 270.14952. Spectroscopic data are in accordance with those described in the literature.²




***N*-(heptan-4-yl)-2-phenoxybenzamide (1d)**

R_f (8:1 hexanes-EtOAc) 0.46. ^1H NMR (500 MHz, CDCl_3) δ 8.23 (dd, $J = 7.9, 1.7$ Hz, 1H), 7.42 – 7.29 (m, 4H), 7.23 (t, $J = 7.6$ Hz, 1H), 7.15 (t, $J = 7.4$ Hz, 1H), 6.98 (d, $J = 8.0$ Hz, 2H), 6.88 (d, $J = 8.2$ Hz, 1H), 4.13 (d, $J = 8.4$ Hz, 1H), 1.50 – 1.42 (m, 2H), 1.36 – 1.23 (m, 6H), 0.82 (t, $J = 7.2$ Hz, 6H). ^{13}C NMR (125 MHz, CDCl_3) δ 164.1, 156.1, 154.4, 132.4, 132.2, 130.0, 125.3, 124.2, 124.1, 119.4, 118.4, 49.1, 37.4, 19.0, 14.0. HRMS (ESI⁺): calcd for $\text{C}_{20}\text{H}_{26}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 312.19635, found 312.19671.




***N*-cyclopentyl-2-phenoxybenzamide (1e)**

R_f (6:1 hexanes-EtOAc) 0.42. ^1H NMR (400 MHz, CDCl_3) δ 8.21 (dd, $J = 7.8, 1.6$ Hz, 1H), 7.59 (s, 1H), 7.35 (t, $J = 7.9$ Hz, 3H), 7.17 (dt, $J = 19.3, 7.5$ Hz, 2H), 6.98 (d, $J = 8.0$ Hz, 2H), 6.85 (d, $J = 8.2$ Hz, 1H), 4.42 – 4.30 (m, 1H), 2.00 – 1.89 (m, 2H), 1.62 – 1.51 (m, 4H), 1.44 – 1.34 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 164.0, 155.8, 154.5, 132.3, 132.0, 130.0, 124.8, 124.1, 123.9, 119.0, 118.4, 51.3, 33.0, 23.5. HRMS (ESI⁺): calcd for $\text{C}_{18}\text{H}_{20}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 282.14940, found 282.14987. Spectroscopic data are in accordance with those described in the literature.²




***N*-cyclohexyl-2-phenoxybenzamide (1f)**

R_f (8:1 hexanes-EtOAc) 0.37. ^1H NMR (500 MHz, CDCl_3) δ 8.21 (dd, $J = 7.9, 1.7$ Hz, 1H), 7.54 (s, 1H), 7.35 (t, $J = 8.1$ Hz, 3H), 7.17 (dt, $J = 23.8, 7.6$ Hz, 2H), 6.99 (d, $J = 7.9$ Hz, 2H), 6.85 (d, $J = 8.2$ Hz, 1H), 4.01 – 3.92 (m, 1H), 1.91 – 1.85 (m, 2H), 1.64 – 1.58 (m, 2H), 1.56 – 1.51 (m, 1H), 1.38 – 1.32 (m, 2H), 1.21 – 1.12 (m, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 163.5, 155.8, 154.6, 132.3, 132.0, 130.0, 125.0, 124.1, 123.9, 119.0, 118.6, 48.0, 32.6, 25.5, 24.4. HRMS (ESI $^+$): calcd for $\text{C}_{19}\text{H}_{22}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 296.16505, found 296.16513. Spectroscopic data are in accordance with those described in the literature.²



***N*-cycloheptyl-2-phenoxybenzamide (1g)**


R_f (8:1 hexanes-EtOAc) 0.40. ^1H NMR (400 MHz, CDCl_3) δ 8.21 (dd, $J = 7.8, 1.6$ Hz, 1H), 7.63 (s, 1H), 7.35 (t, $J = 8.0$ Hz, 3H), 7.22 – 7.12 (m, 2H), 6.99 (d, $J = 7.8$ Hz, 2H), 6.85 (d, $J = 8.2$ Hz, 1H), 4.23 – 4.08 (m, 1H), 1.89 (t, $J = 10.3$ Hz, 2H), 1.59 – 1.42 (m, 10H). ^{13}C NMR (100 MHz, CDCl_3) δ 163.3, 155.8, 154.6, 132.3, 132.0, 130.0, 124.9, 124.1, 123.9, 118.9, 118.6, 50.3, 34.6, 27.8, 23.9. HRMS (ESI $^+$): calcd for $\text{C}_{20}\text{H}_{24}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 310.18070, found 310.18087. Spectroscopic data are in accordance with those described in the literature.²



2-phenoxy-*N*-phenylbenzamide (1h)


R_f (10:1 hexanes-EtOAc) 0.43. ^1H NMR (500 MHz, CDCl_3) δ 9.66 (s, 1H), 8.36 (dd, $J = 7.9, 1.7$ Hz, 1H), 7.64 (d, $J = 7.8$ Hz, 2H), 7.43 (t, $J = 8.0$ Hz, 3H), 7.33 (t, $J = 7.9$ Hz, 2H), 7.25 (dt, $J = 18.8, 7.4$ Hz, 2H), 7.12 (dd, $J = 13.9, 7.6$ Hz, 3H), 6.91 (d, $J = 8.2$ Hz, 1H). ^{13}C NMR (125 MHz, CDCl_3) δ 162.6, 155.3, 155.2, 138.1, 133.1, 132.4, 130.3, 128.9, 124.9, 124.3, 124.1, 123.9, 120.3, 119.4, 118.4. HRMS (ESI $^+$): calcd for $\text{C}_{19}\text{H}_{16}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 290.11810, found 290.11887. Spectroscopic data are in accordance

with those described in the literature.²




***N*-benzyl-2-phenoxybenzamide (1i)**

R_f (6:1 hexanes-EtOAc) 0.32. ^1H NMR (500 MHz, CDCl_3) δ 8.26 (dd, $J = 7.9, 1.8$ Hz, 1H), 7.99 (s, 1H), 7.36 – 7.30 (m, 3H), 7.24 – 7.13 (m, 7H), 6.95 (dd, $J = 8.6, 0.9$ Hz, 2H), 6.82 (dd, $J = 8.2, 0.8$ Hz, 1H), 4.62 (d, $J = 5.7$ Hz, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 164.6, 155.4, 155.0, 138.2, 132.5, 132.1, 130.0, 128.4, 127.2, 127.0, 124.3, 124.1, 123.4, 119.0, 118.5, 43.6. HRMS (ESI⁺): calcd for $\text{C}_{20}\text{H}_{18}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 304.13375, found 304.13367.




***N*-(naphthalen-1-yl)-2-phenoxybenzamide (1j)**

R_f (8:1 hexanes-EtOAc) 0.29. ^1H NMR (500 MHz, CDCl_3) δ 10.22 (s, 1H), 8.42 (dd, $J = 7.9, 1.5$ Hz, 1H), 8.35 (d, $J = 7.6$ Hz, 1H), 7.82 (d, $J = 8.5$ Hz, 1H), 7.78 (d, $J = 8.1$ Hz, 1H), 7.61 (d, $J = 8.2$ Hz, 1H), 7.47 (t, $J = 7.9$ Hz, 1H), 7.38 (td, $J = 7.9, 2.2$ Hz, 4H), 7.30 (dd, $J = 11.3, 3.9$ Hz, 1H), 7.25 – 7.15 (m, 4H), 6.90 (d, $J = 8.2$ Hz, 1H). ^{13}C NMR (125 MHz, CDCl_3) δ 162.9, 155.4, 155.1, 133.9, 133.1, 132.9, 132.5, 130.2, 128.6, 126.4, 126.0, 125.8, 125.6, 124.9, 124.0, 123.8, 120.3, 119.6, 118.2. HRMS (ESI⁺): calcd for $\text{C}_{23}\text{H}_{18}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 340.13375, found 340.13420.




2-(methyl carbamoyl) phenyl 4-methylbenzenesulfonate (1k)

R_f (1:1 hexanes-EtOAc) 0.31. ^1H NMR (500 MHz, CDCl_3) δ 7.82 (dd, $J = 7.7, 1.8$ Hz, 1H), 7.65 (d, $J = 8.3$ Hz, 2H), 7.43 – 7.38 (m, 1H), 7.35 – 7.30 (m, 3H), 7.19 (dd, $J = 8.2, 0.9$ Hz, 1H), 6.57 (s, 1H), 2.85 (d, $J = 4.8$ Hz, 3H), 2.44 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 164.7, 146.2, 146.1, 131.9, 131.6, 131.4, 129.9, 128.7, 128.4, 127.4, 123.0, 26.7, 21.7. HRMS (ESI⁺): calcd for $\text{C}_{15}\text{H}_{16}\text{NO}_4\text{S}$ $[\text{M}+\text{H}]^+$ 306.08000, found 306.08037.




2-hydroxy-*N*-methylbenzamide (1l)

R_f (3:1 hexanes-EtOAc) 0.24. ^1H NMR (500 MHz, CDCl_3) δ 7.39 – 7.33 (m, 2H), 6.97 (d, $J = 8.3$ Hz, 1H), 6.84 – 6.80 (m, 1H), 6.51 (s, 1H), 2.99 (d, $J = 4.8$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 170.6, 161.0, 134.0, 125.6, 118.7, 118.2, 114.3, 26.3. HRMS (ESI $^+$): calcd for $\text{C}_8\text{H}_9\text{NO}_2$ $[\text{M}+\text{H}]^+$ 152.07115, found 152.07146. Spectroscopic data are in accordance with those described in the literature.³




2-methoxy-*N*-methylbenzamide (1m)

R_f (2:1 hexanes-EtOAc) 0.31. ^1H NMR (500 MHz, CDCl_3) δ 8.20 (dd, $J = 7.8, 1.4$ Hz, 1H), 7.82 (s, 1H), 7.43 – 7.39 (m, 1H), 7.05 (t, $J = 7.5$ Hz, 1H), 6.95 (d, $J = 8.3$ Hz, 1H), 3.94 (s, 3H), 2.99 (d, $J = 4.5$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 165.6, 157.0, 132.2, 131.5, 121.0, 120.6, 110.9, 55.4, 26.1. HRMS (ESI $^+$): calcd for $\text{C}_9\text{H}_{12}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 166.08680, found 166.08654. Spectroscopic data are in accordance with those described in the literature.⁴



2-ethoxy-*N*-methylbenzamide (1n)


R_f (2:1 hexanes-EtOAc) 0.27. ^1H NMR (500 MHz, CDCl_3) δ 8.20 (dd, $J = 7.8, 1.8$ Hz, 1H), 7.96 (s, 1H), 7.37 (td, $J = 8.4, 1.8$ Hz, 1H), 7.04 – 7.00 (m, 1H), 6.91 (d, $J = 8.3$ Hz, 1H), 4.15 (q, $J = 7.0$ Hz, 2H), 2.98 (d, $J = 4.8$ Hz, 3H), 1.48 (t, $J = 7.0$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 166.0, 156.7, 132.4, 132.1, 121.5, 121.0, 112.2, 64.53, 26.3, 14.7. HRMS (ESI $^+$): calcd for $\text{C}_{10}\text{H}_{14}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 180.10245, found 180.10271. Spectroscopic data are in accordance with those described in the literature.⁵



4-methoxy-*N*-methyl-2-phenoxybenzamide (1o)


R_f (3:1 hexanes-EtOAc) 0.24. ^1H NMR (500 MHz, CDCl_3) δ 8.23 (d, $J = 8.8$ Hz, 1H),

7.59 (s, 1H), 7.42 – 7.39 (m, 2H), 7.22 (t, $J = 7.4$ Hz, 1H), 7.08 (dd, $J = 8.5, 0.9$ Hz, 2H), 6.71 (dd, $J = 8.9, 2.4$ Hz, 1H), 6.26 (d, $J = 2.4$ Hz, 1H), 3.72 (s, 3H), 2.97 (d, $J = 4.8$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 165.3, 162.9, 157.1, 155.0, 133.7, 130.2, 125.0, 120.1, 116.3, 108.5, 103.8, 55.5, 26.6. HRMS (ESI^+): calcd for $\text{C}_{15}\text{H}_{16}\text{NO}_3$ $[\text{M}+\text{H}]^+$ 258.11302, found 258.11354.




***N*,4-dimethyl-2-phenoxybenzamide (1p)**

R_f (3:1 hexanes-EtOAc) 0.33. ^1H NMR (500 MHz, CDCl_3) δ 8.14 (d, $J = 8.0$ Hz, 1H), 7.62 (s, 1H), 7.42 – 7.36 (m, 2H), 7.22 – 7.17 (m, 1H), 7.07 – 7.02 (m, 2H), 6.99 (dd, $J = 8.0, 0.8$ Hz, 1H), 6.58 (s, 1H), 2.97 (d, $J = 4.8$ Hz, 3H), 2.26 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 165.5, 155.5, 143.5, 132.1, 130.1, 124.6, 124.5, 121.1, 119.9, 118.5, 26.7, 21.3. HRMS (ESI^+): calcd for $\text{C}_{15}\text{H}_{16}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 242.11810, found 242.11833.



***N*-methyl-2-phenoxy-5-(trifluoromethyl) benzamide (1q)**


R_f (3:1 hexanes-EtOAc) 0.39. ^1H NMR (500 MHz, CDCl_3) δ 8.58 (d, $J = 2.2$ Hz, 1H), 7.68 (s, 1H), 7.56 (dd, $J = 8.7, 2.3$ Hz, 1H), 7.49 – 7.45 (m, 2H), 7.30 (t, $J = 7.5$ Hz, 1H), 7.11 (d, $J = 7.7$ Hz, 2H), 6.83 (d, $J = 8.7$ Hz, 1H), 3.04 (d, $J = 4.8$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 164.1, 158.4, 154.2, 130.5, 130.1 (q, $J = 3.75$ Hz), 129.3 (q, $J = 3.75$ Hz), 125.9, 125.5 (q, $J = 32.5$ Hz), 123.7 (q, $J = 272.5$ Hz), 123.5, 120.6, 117.2, 26.9. ^{19}F NMR (471 MHz, CDCl_3) δ -62.1. HRMS (ESI^+): calcd for $\text{C}_{15}\text{H}_{13}\text{F}_3\text{NO}_2$ $[\text{M}+\text{H}]^+$ 296.08984, found 296.08953.



5-methoxy-*N*-methyl-2-phenoxybenzamide (1r)


R_f (3:1 hexanes-EtOAc) 0.30. ^1H NMR (500 MHz, CDCl_3) δ 7.77 (d, $J = 3.2$ Hz, 1H), 7.67 (s, 1H), 7.38 – 7.33 (m, 2H), 7.15 (t, $J = 7.4$ Hz, 1H), 7.01 – 6.97 (m, 2H), 6.93 (dd, $J = 8.9, 3.3$ Hz, 1H), 6.80 (d, $J = 8.9$ Hz, 1H), 3.85 (s, 3H), 2.96 (d, $J = 4.8$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 165.2, 156.6, 155.8, 148.6, 130.0, 125.1, 124.0,

120.8, 119.7, 118.7, 114.7, 55.8, 26.8. HRMS (ESI⁺): calcd for C₁₅H₁₆NO₃ [M+H]⁺ 258.11302, found 258.11325.




N,5-dimethyl-2-phenoxybenzamide (1s)

R_f (3:1 hexanes-EtOAc) 0.50. ¹H NMR (500 MHz, CDCl₃) δ 8.30 (d, *J* = 2.6 Hz, 1H), 7.56 (s, 1H), 7.35 (dd, *J* = 13.5, 5.0 Hz, 3H), 7.16 (t, *J* = 7.4 Hz, 1H), 6.98 (d, *J* = 7.9 Hz, 2H), 6.59 (d, *J* = 8.8 Hz, 1H), 2.92 (d, *J* = 4.8 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 164.0, 154.9, 154.8, 135.2, 134.8, 130.3, 125.2, 125.2, 119.9, 119.6, 116.2, 26.8. HRMS (ESI⁺): calcd for C₁₅H₁₆NO₂ [M+H]⁺ 242.11810, found 242.11867.




N-methyl-2-phenoxy-3-(trifluoromethyl)benzamide (1t)

R_f (3:1 hexanes-EtOAc) 0.21. ¹H NMR (500 MHz, CDCl₃) δ 8.54 (s, 1H), 8.13 (d, *J* = 7.8 Hz, 1H), 7.76 (d, *J* = 7.7 Hz, 1H), 7.39 (s, 1H), 7.20 (d, *J* = 7.6 Hz, 1H), 6.98 (d, *J* = 6.9 Hz, 1H), 6.69 (d, *J* = 8.4 Hz, 3H), 2.68 – 2.62 (m, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 164.4, 158.0, 149.6, 135.5, 130.6, 130.1 (q, *J* = 5.0 Hz), 129.8, 125.8, 125.1 (q, *J* = 32.5 Hz), 123.1, 122.8 (q, *J* = 272.5 Hz), 115.0, 26.6. ¹⁹F NMR (471 MHz, CDCl₃) δ -61.1. HRMS (ESI⁺): calcd for C₁₅H₁₃F₃NO₂ [M+H]⁺ 296.08984, found 296.08993.




3-methoxy-N-methyl-2-phenoxybenzamide (1u)

R_f (3:1 hexanes-EtOAc) 0.21. ¹H NMR (500 MHz, CDCl₃) δ 7.69 (d, *J* = 8.0 Hz, 1H), 7.20 (dt, *J* = 7.1, 4.8 Hz, 4H), 7.02 (d, *J* = 8.1 Hz, 1H), 6.97 (t, *J* = 7.2 Hz, 1H), 6.77 (d, *J* = 8.2 Hz, 2H), 3.64 (s, 3H), 2.83 – 2.78 (m, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 165.3, 157.5, 152.3, 141.4, 129.6, 128.4, 125.8, 123.0, 122.7, 115.6, 115.2, 56.2, 26.7. HRMS (ESI⁺): calcd for C₁₅H₁₆NO₃ [M+H]⁺ 258.11302, found 258.11394.




***N*,3-dimethyl-2-phenoxybenzamide (1v)**

R_f (3:1 hexanes-EtOAc) 0.44. ^1H NMR (500 MHz, CDCl_3) δ 7.85 (d, $J = 7.8$ Hz, 1H), 7.25 – 7.21 (m, 1H), 7.20 – 7.08 (m, 4H), 6.89 (d, $J = 7.5$ Hz, 1H), 6.66 (d, $J = 8.6$ Hz, 2H), 2.70 (d, $J = 4.9$ Hz, 3H), 1.98 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 165.6, 156.8, 149.9, 134.4, 134.3, 131.9, 129.7, 129.3, 127.9, 125.4, 125.4, 122.4, 122.3, 114.9, 26.4, 16.2. HRMS (ESI $^+$): calcd for $\text{C}_{15}\text{H}_{16}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 242.11810, found 242.11823.



3-fluoro-*N*,4-dimethyl-2-phenoxybenzamide (1w)

R_f (3:1 hexanes-EtOAc) 0.36. ^1H NMR (500 MHz, CDCl_3) δ 7.81 (dd, $J = 8.2, 1.0$ Hz, 1H), 7.23 (t, $J = 7.9$ Hz, 3H), 7.08 – 6.99 (m, 2H), 6.84 (d, $J = 8.2$ Hz, 2H), 2.82 (d, $J = 4.9$ Hz, 3H), 2.21 (d, $J = 2.0$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 164.5, 157.2, 153.4 (d, $J = 247.5$ Hz), 140.5 (d, $J = 12.5$ Hz), 130.4 (d, $J = 15.0$ Hz), 129.9, 127.4 (d, $J = 5.0$ Hz), 126.2, 125.9 (d, $J = 3.8$ Hz), 123.4, 115.6, 26.7, 14.6. ^{19}F NMR (471 MHz, CDCl_3) δ -131.5. HRMS (ESI $^+$): calcd for $\text{C}_{15}\text{H}_{15}\text{FNO}_2$ $[\text{M}+\text{H}]^+$ 260.10868, found 260.10844.



4-ethoxy-3-fluoro-*N*-methyl-2-phenoxybenzamide (1x)

R_f (2:1 hexanes-EtOAc) 0.37. ^1H NMR (500 MHz, CDCl_3) δ 7.91 (dd, $J = 9.0, 1.6$ Hz, 1H), 7.22 (dd, $J = 18.1, 10.1$ Hz, 3H), 7.02 (d, $J = 7.3$ Hz, 1H), 6.85 (dd, $J = 16.0, 8.2$ Hz, 3H), 4.08 (d, $J = 7.0$ Hz, 2H), 2.82 (d, $J = 4.8$ Hz, 3H), 1.37 (t, $J = 7.0$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 164.5, 157.0, 150.9 (d, $J = 8.8$ Hz), 144.9 (d, $J = 248.8$ Hz), 141.8 (d, $J = 11.3$ Hz), 129.9, 126.4 (d, $J = 3.8$ Hz), 123.6, 119.9, 115.7, 110.2, 65.1, 26.7, 14.6. ^{19}F NMR (471 MHz, CDCl_3) δ -148.4. HRMS (ESI $^+$): calcd for $\text{C}_{16}\text{H}_{17}\text{FNO}_3$ $[\text{M}+\text{H}]^+$ 290.11925, found 290.11976.

3. Optimizing Reaction Parameters

Table S1. Investigation of the Effect of Time on the *Ortho*-C–O Arylation of Aromatic Amides with Grignard Reagents through Meyers Reaction^a

1a + 2a $\xrightarrow{\text{THF, 60 } ^\circ\text{C, Time}}$ 3a

Entry	Time	3a(%) ^b
1	24	42
2	48	55
3	72	55

^aConditions: **1a** (0.2 mmol), PhMgBr (0.8 mmol), and THF (1.0 mL), under Ar atmosphere at 60 °C for x h. ^bIsolated yield are shown.

Table S2. Investigation of the Effect of Temperature on the *Ortho*-C–O Arylation of Aromatic Amides with Grignard Reagents through Meyers Reaction^a


1a + 2a $\xrightarrow{\text{THF, T } ^\circ\text{C, 48 h}}$ 3a

Entry	T °C	3a(%) ^b
1	rt	25
2	60	55
3	70	62
4	80	70
5	90	83
6	100	92


^aConditions: **1a** (0.2 mmol), PhMgBr (0.8 mmol), and THF (1.0 mL), under Ar atmosphere at T °C for 48 h. ^bIsolated yield are shown.

Table S3. Investigation of the Effect of the Amount of PhMgBr on the *Ortho*-C–O Arylation of Aromatic Amides with Grignard Reagents through Meyers Reaction^a

4. General Procedure for the *Ortho*-C–O Arylation of Aromatic Amides with Grignard Reagents through Meyers Reaction




A dried Schlenk tube were placed aryl ethers **1** (0.4 mmol), phenylmagnesium bromide **2** (1.6 mmol) and freshly distilled THF (2.0 mL) under Ar atmosphere reacted at 100 °C for 48 h. The resulting mixture was quenched by an aqueous solution of NH₄Cl and extraction with ethyl acetate (3 x 10 mL). The combined organic phase was dried over anhydrous Na₂SO₄ and concentrated under vacuum. The crude product was purified by silica gel chromatography to give the desired product **3**.




N-methyl-[1,1'-biphenyl]-2-carboxamide (**3a**)

R_f (4:1 hexanes-EtOAc) 0.35. ¹H NMR (500 MHz, CDCl₃) δ 7.64 (d, *J* = 7.5 Hz, 1H), 7.45 (t, *J* = 7.5 Hz, 1H), 7.40 – 7.34 (m, 7H), 5.32 (s, 1H), 2.64 (d, *J* = 4.9 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 170.2, 140.1, 139.3, 135.7, 130.0, 123.0, 128.7, 128.5, 128.5, 127.6, 127.5, 26.5. HRMS (ESI⁺): calcd for C₁₄H₁₄NO [M+H]⁺ 212.10754, found 212.10852. Spectroscopic data are in accordance with those described in the literature.⁶




N-isopropyl-[1,1'-biphenyl]-2-carboxamide (**3b**)

R_f (6:1 hexanes-EtOAc) 0.25. ¹H NMR (500 MHz, CDCl₃) δ 7.72 (dd, *J* = 7.6, 1.3 Hz, 1H), 7.46 (dd, *J* = 7.5, 1.4 Hz, 1H), 7.43 – 7.37 (m, 6H), 7.35 (dd, *J* = 7.6, 1.1 Hz, 1H), 4.95 (d, *J* = 6.1 Hz, 1H), 4.04 – 3.96 (m, 1H), 0.83 (d, *J* = 6.6 Hz, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 168.3, 140.3, 139.4, 136.0, 130.0, 129.9, 128.8, 128.8, 128.7, 127.7, 127.6, 41.5, 22.1. HRMS (ESI⁺): calcd for C₁₆H₁₈NO [M+H]⁺ 240.13884, found 240.13749.




***N*-(*tert*-butyl)-[1,1'-biphenyl]-2-carboxamide (3c)**

R_f (6:1 hexanes-EtOAc) 0.33. ^1H NMR (500 MHz, CDCl_3) δ 7.73 (dd, $J = 7.6, 1.2$ Hz, 1H), 7.46 – 7.39 (m, 7H), 7.33 (dd, $J = 7.5, 1.1$ Hz, 1H), 4.99 (s, 1H), 1.10 (s, 9H). ^{13}C NMR (125 MHz, CDCl_3) δ 168.3, 130.0, 129.8, 129.0, 128.9, 128.6, 127.7, 127.6, 51.3, 28.2. HRMS (ESI $^+$): calcd for $\text{C}_{17}\text{H}_{20}\text{NO}$ $[\text{M}+\text{H}]^+$ 254.15449, found 254.15724. Spectroscopic data are in accordance with those described in the literature.⁶




***N*-(heptan-4-yl)-[1,1'-biphenyl]-2-carboxamide (3d)**

R_f (6:1 hexanes-EtOAc) 0.44. ^1H NMR (500 MHz, CDCl_3) δ 7.69 (dd, $J = 7.6, 1.2$ Hz, 1H), 7.48 – 7.44 (m, 1H), 7.43 – 7.37 (m, 6H), 7.34 (dd, $J = 7.5, 1.0$ Hz, 1H), 4.97 (d, $J = 8.7$ Hz, 1H), 3.92 – 3.86 (m, 1H), 1.25 – 1.16 (m, 4H), 1.07 – 1.02 (m, 4H), 0.78 (t, $J = 7.0$ Hz, 6H). ^{13}C NMR (125 MHz, CDCl_3) δ 168.9, 139.3, 130.2, 129.7, 128.8, 128.7, 128.6, 127.7, 127.5, 49.1, 36.8, 29.7, 18.7, 14.0. HRMS (ESI $^+$): calcd for $\text{C}_{20}\text{H}_{26}\text{NO}$ $[\text{M}+\text{H}]^+$ 296.20144, found 296.20357.




***N*-cyclopentyl-[1,1'-biphenyl]-2-carboxamide (3e)**

R_f (6:1 hexanes-EtOAc) 0.23. ^1H NMR (500 MHz, CDCl_3) δ 7.73 (d, $J = 7.6$ Hz, 1H), 7.48 – 7.44 (m, 1H), 7.43 – 7.38 (m, 6H), 7.34 (d, $J = 7.5$ Hz, 1H), 5.08 (d, $J = 6.0$ Hz, 1H), 4.16 (d, $J = 6.9$ Hz, 1H), 1.72 (dd, $J = 13.0, 5.5$ Hz, 2H), 1.43 (dd, $J = 9.8, 5.4$ Hz, 2H), 1.30 (dd, $J = 9.4, 5.7$ Hz, 2H), 0.97 (dd, $J = 12.4, 6.3$ Hz, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 168.6, 140.4, 139.4, 135.9, 130.0, 129.9, 128.9, 128.7, 128.6, 127.8, 127.6, 51.3, 32.5, 23.4. HRMS (ESI $^+$): calcd for $\text{C}_{18}\text{H}_{20}\text{NO}$ $[\text{M}+\text{H}]^+$ 266.15449, found 266.15502.




***N*-cyclohexyl-[1,1'-biphenyl]-2-carboxamide (3f)**


R_f (6:1 hexanes-EtOAc) 0.30. ^1H NMR (500 MHz, CDCl_3) δ 7.72 (dd, $J = 7.6, 1.3$ Hz, 1H), 7.46 (td, $J = 7.5, 1.5$ Hz, 1H), 7.44 – 7.33 (m, 8H), 5.04 (d, $J = 7.5$ Hz, 1H), 3.73 (ddd, $J = 10.3, 4.0, 2.1$ Hz, 1H), 1.61 (dd, $J = 8.6, 3.9$ Hz, 2H), 1.49 (d, $J = 9.6$ Hz, 3H), 1.28 – 1.19 (m, 3H), 0.72 (td, $J = 13.2, 3.0$ Hz, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 168.3, 140.3, 139.4, 136.1, 130.1, 129.9, 128.9, 128.8, 128.6, 127.7, 127.6, 48.2, 32.4, 25.4, 24.5. HRMS (ESI⁺): calcd for $\text{C}_{19}\text{H}_{22}\text{NO}$ $[\text{M}+\text{H}]^+$ 280.17014, found 280.17202.

***N*-cycloheptyl-[1,1'-biphenyl]-2-carboxamide (3g)**


R_f (6:1 hexanes-EtOAc) 0.31. ^1H NMR (500 MHz, CDCl_3) δ 7.72 (dd, $J = 7.6, 1.3$ Hz, 1H), 7.46 (td, $J = 7.5, 1.5$ Hz, 1H), 7.43 – 7.37 (m, 6H), 7.34 (dd, $J = 7.6, 1.2$ Hz, 1H), 5.11 (d, $J = 7.5$ Hz, 1H), 3.91 (dd, $J = 13.1, 4.4$ Hz, 1H), 1.65 – 1.60 (m, 2H), 1.53 – 1.46 (m, 2H), 1.37 – 1.31 (m, 6H), 1.03 (dd, $J = 10.3, 5.1$ Hz, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 168.0, 140.4, 139.3, 136.2, 130.1, 129.9, 128.9, 128.8, 128.6, 127.7, 127.6, 50.4, 34.3, 28.1, 23.7. HRMS (ESI⁺): calcd for $\text{C}_{20}\text{H}_{24}\text{NO}$ $[\text{M}+\text{H}]^+$ 294.18579, found 294.18631.

***N*-phenyl-[1,1'-biphenyl]-2-carboxamide (3h)**

R_f (6:1 hexanes-EtOAc) 0.42. ^1H NMR (500 MHz, CDCl_3) δ 7.90 (d, $J = 7.1$ Hz, 1H), 7.55 (td, $J = 7.5, 1.1$ Hz, 1H), 7.51 – 7.40 (m, 7H), 7.23 (t, $J = 7.8$ Hz, 2H), 7.11 (d, $J = 7.8$ Hz, 2H), 7.05 (t, $J = 7.4$ Hz, 1H), 6.90 (s, 1H). ^{13}C NMR (125 MHz, CDCl_3) δ 167.1, 139.9, 139.5, 137.5, 135.2, 130.7, 130.3, 129.6, 129.0, 128.8, 128.8, 128.1, 127.9, 124.4, 119.9. HRMS (ESI⁺): calcd for $\text{C}_{19}\text{H}_{16}\text{NO}$ $[\text{M}+\text{H}]^+$ 274.12319, found 274.12357. Spectroscopic data are in accordance with those described in the literature.⁶


***N*-benzyl-[1,1'-biphenyl]-2-carboxamide (3i)**

R_f (5:1 hexanes-EtOAc) 0.28. ^1H NMR (500 MHz, CDCl_3) δ 7.61 (dd, $J = 7.6, 1.3$ Hz, 1H), 7.39 – 7.24 (m, 8H), 7.13 – 7.07 (m, 3H), 6.78 (dd, $J = 6.4, 3.0$ Hz, 2H), 5.46 (s, 1H), 4.22 (d, $J = 5.6$ Hz, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 169.3, 140.1, 139.4, 137.4, 135.5, 130.2, 130.1, 128.8, 128.7, 128.6, 128.5, 127.7, 127.5, 127.3, 44.1. HRMS (ESI^+): calcd for $\text{C}_{20}\text{H}_{18}\text{NO}$ $[\text{M}+\text{H}]^+$ 288.13884, found 288.13876. Spectroscopic data are in accordance with those described in the literature.⁶




***N*-(naphthalen-1-yl)-[1,1'-biphenyl]-2-carboxamide (3j)**

R_f (6:1 hexanes-EtOAc) 0.22. ^1H NMR (500 MHz, CDCl_3) δ 7.96 (t, $J = 7.1$ Hz, 2H), 7.77 (d, $J = 8.2$ Hz, 1H), 7.66 – 7.55 (m, 4H), 7.54 – 7.35 (m, 8H), 7.24 – 7.19 (m, 1H), 6.62 (d, $J = 8.5$ Hz, 1H). ^{13}C NMR (125 MHz, CDCl_3) δ 168.0, 140.1, 139.2, 135.9, 133.8, 132.1, 130.6, 130.6, 129.7, 129.1, 128.4, 128.2, 127.9, 126.6, 125.8, 125.7, 125.6, 125.4, 120.1, 119.9. HRMS (ESI^+): calcd for $\text{C}_{23}\text{H}_{18}\text{NO}$ $[\text{M}+\text{H}]^+$ 324.13884, found 324.13826. Spectroscopic data are in accordance with those described in the literature.⁶



5-methoxy-*N*-methyl-[1,1'-biphenyl]-2-carboxamide (3k)


R_f (1:1 hexanes-EtOAc) 0.61. ^1H NMR (500 MHz, CDCl_3) δ 7.69 (d, $J = 8.6$ Hz, 1H), 7.44 – 7.34 (m, 5H), 6.91 (dd, $J = 8.6, 2.5$ Hz, 1H), 6.83 (d, $J = 2.5$ Hz, 1H), 5.16 (s, 1H), 3.84 (s, 3H), 2.63 (d, $J = 4.9$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 169.7, 160.7, 141.3, 140.3, 131.0, 128.6, 127.9, 115.4, 113.0, 55.4, 26.6. HRMS (ESI^+): calcd for $\text{C}_{15}\text{H}_{16}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 242.11810, found 242.11135. Spectroscopic data are in accordance with those described in the literature.⁷



***N*,5-dimethyl-[1,1'-biphenyl]-2-carboxamide (3l)**

R_f (2:1 hexanes-EtOAc) 0.32. ^1H NMR (500 MHz, CDCl_3) δ 7.62 (d, $J = 7.8$ Hz, 1H), 7.43 – 7.34 (m, 5H), 7.22 (d, $J = 7.9$ Hz, 1H), 7.17 (s, 1H), 5.13 (s, 1H), 2.66 (d, $J = 4.9$


Hz, 3H), 2.41 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 170.7, 140.5, 140.1, 139.5, 132.0, 130.9, 129.0, 128.6, 128.5, 128.3, 127.7, 26.8, 21.3. HRMS (ESI^+): calcd for $\text{C}_{15}\text{H}_{16}\text{NO}$ $[\text{M}+\text{H}]^+$ 226.12319, found 226.12587. Spectroscopic data are in accordance with those described in the literature.⁷



***N*-methyl-4-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxamide (3m)**


R_f (3:1 hexanes-EtOAc) 0.42. ^1H NMR (500 MHz, CDCl_3) δ 7.97 (s, 1H), 7.72 (dd, J = 8.0, 1.3 Hz, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.49 – 7.40 (m, 5H), 5.23 (s, 1H), 2.70 (d, J = 4.9 Hz, 3H).

^{13}C NMR (125 MHz, CDCl_3) δ 168.8, 142.8, 138.7, 136.3, 130.7, 128.7, 128.4, 126.5, 125.8, 125.7, 125.7, 124.8, 122.6, 26.5. ^{19}F NMR (471 MHz, CDCl_3) δ -62.6. HRMS (ESI^+): calcd for $\text{C}_{15}\text{H}_{13}\text{F}_3\text{NO}$ $[\text{M}+\text{H}]^+$ 280.09492, found 280.09486.




4-methoxy-*N*-methyl-[1,1'-biphenyl]-2-carboxamide (3n)

R_f (1:1 hexanes-EtOAc) 0.38. ^1H NMR (500 MHz, CDCl_3) δ 7.42 – 7.28 (m, 6H), 7.25 (d, J = 2.7 Hz, 1H), 7.02 (dd, J = 8.5, 2.8 Hz, 1H), 5.16 (s, 1H), 3.87 (s, 3H), 2.67 (d, J = 5.0 Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 170.0, 159.0, 139.9, 136.6, 131.8, 131.4, 128.7, 128.6, 127.4, 116.9, 113.2, 55.5, 26.7. HRMS (ESI^+): calcd for $\text{C}_{15}\text{H}_{16}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 242.11810, found 242.11175.




***N*,4-dimethyl-[1,1'-biphenyl]-2-carboxamide (3o)**

R_f (3:1 hexanes-EtOAc) 0.35. ^1H NMR (500 MHz, CDCl_3) δ 7.43 (s, 1H), 7.34 – 7.30 (m, 4H), 7.29 – 7.25 (m, 1H), 7.20 (dd, J = 4.8, 1.8 Hz, 2H), 5.11 (s, 1H), 2.59 (d, J = 5.0 Hz, 3H), 2.33 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 170.4, 140.1, 137.5, 136.4, 135.5, 130.9, 130.1, 129.4, 128.6, 128.5, 127.5, 26.6, 21.0. HRMS (ESI^+): calcd for $\text{C}_{15}\text{H}_{16}\text{NO}$ $[\text{M}+\text{H}]^+$ 226.12319, found 226.12254. Spectroscopic data are in accordance with those described in the literature.⁶




***N*-methyl-6-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxamide (3p)**

R_f (2:1 hexanes-EtOAc) 0.20. ^1H NMR (500 MHz, CDCl_3) δ 7.83 (dd, $J = 11.1, 7.9$ Hz, 2H), 7.53 (t, $J = 7.8$ Hz, 1H), 7.44 – 7.38 (m, 3H), 7.32 – 7.26 (m, 2H), 5.12 (s, 1H), 2.53 (d, $J = 4.9$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 168.5, 138.9, 138.0, 136.4, 131.7, 129.4 (q, $J = 30.0$ Hz), 129.1, 128.4, 128.1, 127.9, 127.5 (q, $J = 5.0$ Hz), 123.5 (q, $J = 227.5$ Hz), 26.6. ^{19}F NMR (471 MHz, CDCl_3) δ -56.9. HRMS (ESI $^+$): calcd for $\text{C}_{15}\text{H}_{13}\text{F}_3\text{NO}$ $[\text{M}+\text{H}]^+$ 280.09492, found 280.09477.




6-methoxy-*N*-methyl-[1,1'-biphenyl]-2-carboxamide (3q)

R_f (4:1 hexanes-EtOAc) 0.39. ^1H NMR (500 MHz, CDCl_3) δ 7.69 (d, $J = 8.6$ Hz, 1H), 7.44 – 7.34 (m, 5H), 6.91 (dd, $J = 8.6, 2.5$ Hz, 1H), 6.83 (d, $J = 2.5$ Hz, 1H), 5.16 (s, 1H), 3.84 (s, 3H), 2.63 (d, $J = 4.9$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 165.3, 157.4, 152.3, 141.3, 129.6, 128.4, 125.9, 123.0, 122.7, 115.6, 115.1, 56.2, 26.7. HRMS (ESI $^+$): calcd for $\text{C}_{15}\text{H}_{16}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 242.11810, found 242.11074.




***N*,6-dimethyl-[1,1'-biphenyl]-2-carboxamide (3r)**

R_f (3:1 hexanes-EtOAc) 0.20. ^1H NMR (500 MHz, CDCl_3) δ 7.42 (d, $J = 7.4$ Hz, 1H), 7.34 (t, $J = 7.4$ Hz, 2H), 7.29 – 7.20 (m, 3H), 7.14 (d, $J = 7.1$ Hz, 2H), 5.16 (s, 1H), 2.46 (d, $J = 4.9$ Hz, 3H), 2.04 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 170.1, 139.4, 138.7, 136.6, 136.4, 131.7, 128.9, 128.5, 127.5, 125.9, 26.5, 20.7. HRMS (ESI $^+$): calcd for $\text{C}_{15}\text{H}_{16}\text{NO}$ $[\text{M}+\text{H}]^+$ 226.12319, found 226.12261.




6-fluoro-*N*,5-dimethyl-[1,1'-biphenyl]-2-carboxamide (3s)

R_f (2:1 hexanes-EtOAc) 0.23. ^1H NMR (500 MHz, CDCl_3) δ 7.40 – 7.28 (m, 6H), 7.17 (t, $J = 7.7$ Hz, 1H), 5.02 (s, 1H), 2.53 (d, $J = 4.9$ Hz, 3H), 2.26 (d, $J = 2.1$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 168.6, 157.7 (d, $J = 243.8$ Hz), 135.4 (d, $J = 2.5$ Hz), 133.6, 130.6 (d, $J = 5.0$ Hz), 129.6, 128.5, 128.2, 127.5 (d, $J = 18.8$ Hz), 126.7 (d, $J = 17.5$ Hz), 124.0, 26.6, 14.9. ^{19}F NMR (471 MHz, CDCl_3) δ -118.9. HRMS (ESI $^+$): calcd for $\text{C}_{15}\text{H}_{15}\text{FNO}$ $[\text{M}+\text{H}]^+$ 244.11377, found 244.11362.




5-ethoxy-6-fluoro-*N*-methyl-[1,1'-biphenyl]-2-carboxamide (3t)

R_f (1:1 hexanes-EtOAc) 0.52. ^1H NMR (500 MHz, CDCl_3) δ 7.57 – 7.53 (m, 1H), 7.46 – 7.35 (m, 5H), 7.02 – 6.96 (m, 1H), 5.05 (s, 1H), 4.20 – 4.14 (m, 2H), 2.58 (dd, $J = 4.8, 2.9$ Hz, 3H), 1.50 – 1.44 (m, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 168.2, 149.0 (d, $J = 245.0$ Hz), 148.8 (d, $J = 12.5$ Hz), 133.2, 129.6, 128.6, 128.5 (d, $J = 10.0$ Hz), 128.4, 128.1 (d, $J = 13.8$ Hz), 125.1, 125.1 (d, $J = 8.8$ Hz), 113.0, 64.9, 26.6, 14.7. ^{19}F NMR (471 MHz, CDCl_3) δ -136.5. HRMS (ESI $^+$): calcd for $\text{C}_{16}\text{H}_{17}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 274.12433, found 274.12456.




4'-methoxy-*N*-methyl-[1,1'-biphenyl]-2-carboxamide (3u)

R_f (2:1 hexanes-EtOAc) 0.37. ^1H NMR (500 MHz, CDCl_3) δ 7.69 (d, $J = 8.6$ Hz, 1H), 7.44 – 7.34 (m, 5H), 6.91 (dd, $J = 8.6, 2.5$ Hz, 1H), 6.83 (d, $J = 2.5$ Hz, 1H), 5.16 (s, 1H), 3.84 (s, 3H), 2.63 (d, $J = 4.9$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 170.5, 159.3, 138.9, 135.5, 132.4, 130.1, 129.8, 128.8, 127.2, 114.0, 55.3, 26.7. HRMS (ESI $^+$): calcd for $\text{C}_{15}\text{H}_{16}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 242.11810, found 242.11795.




***N*,4'-dimethyl-[1,1'-biphenyl]-2-carboxamide (3v)**

R_f (3:1 hexanes-EtOAc) 0.21. ^1H NMR (500 MHz, CDCl_3) δ 7.68 (dd, $J = 7.6, 1.2$ Hz, 1H), 7.45 (td, $J = 7.5, 1.4$ Hz, 1H), 7.41 – 7.33 (m, 2H), 7.30 (d, $J = 8.1$ Hz, 2H), 7.22 (d, $J = 7.9$ Hz, 2H), 5.24 (s, 1H), 2.69 (d, $J = 4.9$ Hz, 3H), 2.39 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 170.4, 139.3, 137.5, 137.2, 135.5, 130.1, 129.3, 128.8, 128.5, 127.4, 26.7, 21.2. HRMS (ESI $^+$): calcd for $\text{C}_{15}\text{H}_{16}\text{NO}$ $[\text{M}+\text{H}]^+$ 226.12319, found 226.12335. Spectroscopic data are in accordance with those described in the literature.⁸



3'-methoxy-*N*-methyl-[1,1'-biphenyl]-2-carboxamide (3w)


R_f (2:1 hexanes-EtOAc) 0.31. ^1H NMR (500 MHz, CDCl_3) δ 7.65 (dd, $J = 7.6, 0.8$ Hz, 1H), 7.45 (td, $J = 7.5, 1.3$ Hz, 1H), 7.40 – 7.34 (m, 2H), 7.31 (t, $J = 7.9$ Hz, 1H), 6.92 (ddd, $J = 13.5, 10.1, 4.7$ Hz, 3H), 5.34 (s, 1H), 3.81 (s, 3H), 2.67 (d, $J = 4.9$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 170.2, 159.6, 141.6, 139.2, 135.7, 130.0, 129.6, 128.8, 127.6, 121.0, 113.9, 113.5, 55.3, 26.6. HRMS (ESI $^+$): calcd for $\text{C}_{15}\text{H}_{16}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 242.11810, found 242.11824.



***N*,3'-dimethyl-[1,1'-biphenyl]-2-carboxamide (3x)**


R_f (2:1 hexanes-EtOAc) 0.35. ^1H NMR (500 MHz, CDCl_3) δ 7.69 (dd, $J = 7.6, 1.2$ Hz, 1H), 7.45 (td, $J = 7.5, 1.4$ Hz, 1H), 7.40 – 7.34 (m, 2H), 7.30 (t, $J = 7.5$ Hz, 1H), 7.19 (dd, $J = 17.9, 8.2$ Hz, 3H), 5.23 (s, 1H), 2.67 (d, $J = 4.9$ Hz, 3H), 2.39 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 170.2, 140.1, 139.4, 138.3, 135.6, 130.1, 130.0, 129.3, 128.8, 128.5, 128.4, 127.5, 125.7, 26.6, 21.4. HRMS (ESI $^+$): calcd for $\text{C}_{15}\text{H}_{16}\text{NO}$ $[\text{M}+\text{H}]^+$

226.12319, found 226.12327. Spectroscopic data are in accordance with those described in the literature.⁹




***N*-methyl-[1,1':4',1''-terphenyl]-2-carboxamide (3y)**

R_f (2:1 hexanes-EtOAc) 0.26. ^1H NMR (500 MHz, CDCl_3) δ 7.67 (dt, $J = 14.6, 8.0$ Hz, 5H), 7.51 – 7.36 (m, 8H), 5.35 (d, $J = 4.1$ Hz, 1H), 2.71 (d, $J = 4.9$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 170.3, 140.4, 140.3, 139.0, 138.8, 135.7, 130.1, 129.0, 128.8, 127.6, 127.5, 127.2, 127.0, 26.7. HRMS (ESI^+): calcd for $\text{C}_{20}\text{H}_{18}\text{NO}$ $[\text{M}+\text{H}]^+$ 288.13884, found 288.13876.



3'-fluoro-*N*-methyl-[1,1'-biphenyl]-2-carboxamide (3z)


R_f (2:1 hexanes-EtOAc) 0.29. ^1H NMR (500 MHz, CDCl_3) δ 7.65 (dd, $J = 7.6, 1.1$ Hz, 1H), 7.49 – 7.35 (m, 4H), 7.20 – 7.04 (m, 3H), 5.28 (s, 1H), 2.73 (d, $J = 4.9$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 170.0, 162.7 (d, $J = 245.0$ Hz), 142.4 (d, $J = 8.8$ Hz), 138.1, 135.9, 130.2, 130.1, 130.0, 128.7, 128.1, 124.4 (d, $J = 2.5$ Hz), 115.5 (d, $J = 21.3$ Hz), 114.6 (d, $J = 20.0$ Hz), 26.7. ^{19}F NMR (471 MHz, CDCl_3) δ -112.7. HRMS (ESI^+): calcd for $\text{C}_{14}\text{H}_{13}\text{FNO}$ $[\text{M}+\text{H}]^+$ 230.09812, found 230.09835.



4'-fluoro-*N*-methyl-[1,1'-biphenyl]-2-carboxamide (3aa)


R_f (2:1 hexanes-EtOAc) 0.31. ^1H NMR (500 MHz, CDCl_3) δ 7.63 (dd, $J = 7.6, 1.1$ Hz, 1H), 7.49 – 7.33 (m, 5H), 7.15 – 7.07 (m, 2H), 5.28 (s, 1H), 2.71 (d, $J = 4.9$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 170.2, 162.5 (d, $J = 246.3$ Hz), 138.3, 136.1 (d, $J = 3.8$ Hz), 135.9, 130.3, 130.2 (d, $J = 11.3$ Hz), 130.1, 128.6, 127.7, 115.5 (d, $J = 21.3$ Hz),

26.7. ^{19}F NMR (471 MHz, CDCl_3) δ -114.5. HRMS (ESI^+): calcd for $\text{C}_{14}\text{H}_{13}\text{FNO}$ $[\text{M}+\text{H}]^+$ 230.09812, found 230.09835. Spectroscopic data are in accordance with those described in the literature.¹⁰




4'-chloro-*N*-methyl-[1,1'-biphenyl]-2-carboxamide (3ab)

R_f (2:1 hexanes-EtOAc) 0.27. ^1H NMR (500 MHz, CDCl_3) δ 7.65 (dd, $J = 7.5, 1.1$ Hz, 1H), 7.51 – 7.34 (m, 5H), 7.22 – 7.03 (m, 3H), 5.26 (s, 1H), 2.73 (dd, $J = 4.9, 3.0$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 170.0, 163.7, 162.0, 142.4, 138.1, 135.9, 130.2, 130.09, 130.0, 129.9, 128.8, 128.7, 128.1, 124.4, 115.6, 115.4, 114.7, 114.6, 26.7. HRMS (ESI^+): calcd for $\text{C}_{14}\text{H}_{13}\text{ClNO}$ $[\text{M}+\text{H}]^+$ 246.06857, found 246.06879.



4'-(dimethylamino)-*N*-methyl-[1,1'-biphenyl]-2-carboxamide (3ac)

R_f (1:1 hexanes-EtOAc) 0.38. ^1H NMR (500 MHz, CDCl_3) δ 7.71 – 7.66 (m, 1H), 7.44 – 7.40 (m, 1H), 7.35 – 7.27 (m, 4H), 6.78 – 6.74 (m, 2H), 5.32 (d, $J = 3.0$ Hz, 1H), 2.99 (s, 6H), 2.71 (d, $J = 4.9$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 170.7, 150.0, 139.4, 135.0, 130.0, 129.5, 129.0, 127.6, 126.6, 112.3, 40.4, 26.7. HRMS (ESI^+): calcd for $\text{C}_{15}\text{H}_{16}\text{NO}$ $[\text{M}+\text{H}]^+$ 255.14974, found 255.14738.




***N*,2'-dimethyl-[1,1'-biphenyl]-2-carboxamide (3ad)**

R_f (2:1 hexanes-EtOAc) 0.31. ^1H NMR (500 MHz, CDCl_3) δ 7.85 (dd, $J = 7.6, 1.4$ Hz, 1H), 7.43 – 7.35 (m, 2H), 7.25 – 7.19 (m, 3H), 7.15 – 7.10 (m, 2H), 5.16 (s, 1H), 2.55 (d, $J = 4.9$ Hz, 3H), 2.04 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 168.9, 140.2, 139.1, 136.1, 134.8, 130.4, 130.3, 129.3, 129.1, 128.2, 127.7, 126.2, 26.7, 20.0. HRMS (ESI^+): calcd for $\text{C}_{15}\text{H}_{16}\text{NO}$ $[\text{M}+\text{H}]^+$ 226.12319, found 226.12397. Spectroscopic data are in accordance with those described in the literature.⁸


5. Supplementary References

1. Zhang, X.-L.; Pan, G.-F.; Zhu, X.-Q.; Guo, R.-L.; Gao, Y.-R.; Wang, Y.-Q., Dehydrogenative β -Arylation of Saturated Aldehydes Using Transient Directing Groups. *Organic Letters* **2019**, *21* (8), 2731-2735.
2. Liu, P.; Wu, B.; Cong, X.; Kong, J., Iron-Catalyzed Reductive C(aryl)—Si Cross-Coupling of Diaryl Ethers with Chlorosilanes. *Chinese Journal of Chemistry* **2023**, *42* (6), 578-584.
3. Xia, Q.; Liu, X.; Zhang, Y.; Chen, C.; Chen, W., Copper-Catalyzed *N*-Methylation of Amides and *O*-Methylation of Carboxylic Acids by Using Peroxides as the Methylating Reagents. *Organic Letters* **2013**, *15* (13), 3326-3329.
4. Paul, B.; Maji, M.; Kundu, S., Atom-Economical and Tandem Conversion of Nitriles to *N*-Methylated Amides Using Methanol and Water. *ACS Catalysis* **2019**, *9* (11), 10469-10476.
5. Babu, R.; Padhy, S. R.; Balaraman, E., Efficient *N*-methylation of primary amides using methanol under Mn(I)-catalysis. *Tetrahedron* **2025**, *176*.
6. Usami, K.; Yamaguchi, E.; Tada, N.; Itoh, A., Transition-Metal-Free Synthesis of Phenanthridinones through Visible-Light-Driven Oxidative C–H Amidation. *European Journal of Organic Chemistry* **2019**, *2020* (10), 1496-1504.
7. Chinnagolla, R. K.; Jeganmohan, M., Regioselective Ortho-Arylation and Alkenylation of *N*-Alkyl Benzamides with Boronic Acids via Ruthenium-Catalyzed C–H Bond Activation: An Easy Route to Fluorenones Synthesis. *Organic Letters* **2012**, *14* (20), 5246-5249.
8. Gao, P.; Guo, W.; Xue, J.; Zhao, Y.; Yuan, Y.; Xia, Y.; Shi, Z., Iridium(III)-Catalyzed Direct Arylation of C–H Bonds with Diaryliodonium Salts. *Journal of the American Chemical Society* **2015**, *137* (38), 12231-12240.
9. Li, J.; Ackermann, L., Cobalt-Catalyzed C–H Arylations with Weakly-Coordinating Amides and Tetrazoles: Expedient Route to Angiotensin-II-Receptor Blockers. *Chemistry - A European Journal* **2015**, *21* (15), 5718-5722.
10. Shin, K.; Park, S.-W.; Chang, S., Cp*Ir(III)-Catalyzed Mild and Broad C–H Arylation of Arenes and Alkenes with Aryldiazonium Salts Leading to the External Oxidant-Free Approach. *Journal of the American Chemical Society* **2015**, *137* (26), 8584-8592.


6. ^1H , ^{13}C and ^{19}F NMR Spectra




^1H and ^{13}C NMR spectra in CDCl₃ for compound **1a**





¹H and ¹³C NMR spectra in CDCl₃ for compound **1b**




¹H and ¹³C NMR spectra in CDCl₃ for compound 1c




¹H and ¹³C NMR spectra in CDCl₃ for compound 1d





¹H and ¹³C NMR spectra in CDCl₃ for compound **1e**




^1H and ^{13}C NMR spectra in CDCl₃ for compound 1f




¹H and ¹³C NMR spectra in CDCl₃ for compound **1g**




¹H and ¹³C NMR spectra in CDCl₃ for compound 1h







¹H and ¹³C NMR spectra in CDCl₃ for compound **1j**




¹H and ¹³C NMR spectra in CDCl₃ for compound **1k**




¹H and ¹³C NMR spectra in CDCl₃ for compound **11**




¹H and ¹³C NMR spectra in CDCl₃ for compound **1m**




¹H and ¹³C NMR spectra in CDCl₃ for compound **1n**




¹H and ¹³C NMR spectra in CDCl₃ for compound **1o**




¹H and ¹³C NMR spectra in CDCl₃ for compound **1p**




¹H and ¹³C NMR spectra in CDCl₃ for compound **1q**





^{19}F NMR spectra in CDCl_3 for compound **1q**







¹H and ¹³C NMR spectra in CDCl₃ for compound **1r**






¹H and ¹³C NMR spectra in CDCl₃ for compound 1s







^{13}C NMR spectra in CDCl_3 for compound **1t**




^{19}F NMR spectra in CDCl_3 for compound **1t**




¹H and ¹³C NMR spectra in CDCl₃ for compound **1u**







¹H and ¹³C NMR spectra in CDCl₃ for compound **1w**




^{19}F NMR spectra in CDCl_3 for compound **1w**







^1H and ^{13}C NMR spectra in CDCl_3 for compound 1x




^{19}F NMR spectra in CDCl_3 for compound 1x




¹H and ¹³C NMR spectra in CDCl₃ for compound 3a




¹H and ¹³C NMR spectra in CDCl₃ for compound 3c







¹H and ¹³C NMR spectra in CDCl₃ for compound **3e**










¹H and ¹³C NMR spectra in CDCl₃ for compound **3i**




^1H and ^{13}C NMR spectra in CDCl_3 for compound **3j**




¹H and ¹³C NMR spectra in CDCl₃ for compound **3k**




¹H and ¹³C NMR spectra in CDCl₃ for compound **3l**




^1H and ^{13}C NMR spectra in CDCl₃ for compound **3m**





^{19}F NMR spectra in CDCl_3 for compound **3m**







¹H and ¹³C NMR spectra in CDCl₃ for compound **3n**






^1H and ^{13}C NMR spectra in CDCl₃ for compound **3o**







¹H and ¹³C NMR spectra in CDCl₃ for compound 3p




¹⁹F NMR spectra in CDCl₃ for compound 3p




¹H and ¹³C NMR spectra in CDCl₃ for compound **3q**




¹H and ¹³C NMR spectra in CDCl₃ for compound 3f




¹H and ¹³C NMR spectra in CDCl₃ for compound **3s**




^{19}F NMR spectra in CDCl_3 for compound **3s**







^1H and ^{13}C NMR spectra in CDCl₃ for compound **3t**





^{19}F NMR spectra in CDCl₃ for compound **3t**




¹H and ¹³C NMR spectra in CDCl₃ for compound **3u**




¹H and ¹³C NMR spectra in CDCl₃ for compound 3v




¹H and ¹³C NMR spectra in CDCl₃ for compound 3w




¹H and ¹³C NMR spectra in CDCl₃ for compound 3x





¹H and ¹³C NMR spectra in CDCl₃ for compound **3y**






^{19}F NMR spectra in CDCl_3 for compound **3z**







¹H and ¹³C NMR spectra in CDCl₃ for compound 3aa




¹⁹F NMR spectra in CDCl₃ for compound 3aa



¹H and ¹³C NMR spectra in CDCl₃ for compound 3ab



^1H and ^{13}C NMR spectra in CDCl₃ for compound **3ac**



¹H and ¹³C NMR spectra in CDCl₃ for compound 3ad